A study of a new drug for active uveitis
Part of Eyes & vision clinical trials.
This study tests a new drug (GenSci048) for people with active, non-infectious uveitis in the middle or back of the eye, who are already taking oral steroids. The goal is to see if the drug can better control inflammation and reduce the need for steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You've had non-infectious uveitis in the back or middle part of your eye for more than one year.
- Your uveitis is active even though you've been taking a stable dose of oral prednisone for at least 2 weeks.
- You've responded well to oral steroids in the past (up to about 1 mg/kg/day of prednisone).
- You have not used a biologic drug (like anti-TNF) for uveitis in the last 12 weeks, and do not have active tuberculosis or other major health issues like uncontrolled high blood pressure, heart failure, or diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic (inherited) differences in people with uveitis. The goal is to better understand what may cause uveitis and potentially help with future treatments.
This study tests a drug called adalimumab, which helps calm the immune system, when added to the steroid medicine you may already be taking. It aims to see if this combination is safe and works better for people with Behçet's disease that affects the back of the eye and has recently flared up.
This trial tests whether a small steroid implant placed inside the eye (YUTIQ 0.18 mg) can control chronic non-infectious uveitis. It may help reduce active inflammation and prevent flare-ups, as long as you’ve had recent signs of active disease and can follow the medication and eye-visit rules.
This trial tests a new drug, GenSci136, in healthy adults to see if it's safe and how the body processes it. If you qualify, you would receive the drug and be monitored for side effects.
This study tests a new drug called GenSci120, given as multiple injections under the skin, to see if it is safe in healthy adults. It will also measure how the drug moves through the body and how it affects certain immune markers.
This trial tests a new drug called FXS5626 to treat non-infectious uveitis—inflammation inside the eye that doesn't come from infection. The study looks at whether this drug can reduce eye inflammation and improve vision in people whose condition isn't controlled with steroid eye drops and oral steroids alone.
Hear when a new Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.